default author photo

Benigno C. Valdez

University of Texas at Houston - MD Anderson Cancer Center

SCHOLARLY PAPERS

1

DOWNLOADS

72

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Safety and Efficacy of a New High-Dose Chemotherapy Regimen of Panobinostat, Gemcitabine, Busulfan and Melphalan for 1st or 2nd Salvage Autologous Stem Cell Transplant for Patients with Refractory/Relapsed or High-Risk Myeloma: Matched Pair Comparisons with Concurrent Control Cohorts

Number of pages: 33 Posted: 10 Aug 2023
Yago Nieto, Zixi Yang, Benigno C. Valdez, Roland Bassett, Suprateek Kundu, Melissa Barnett, Qaiser Bashir, Jeremy Ramdial, Jin Im, Partow Kebriaei, Uday Popat, Neeraj Y. Saini, Samer Srour, Jitesh Kawedia, Alison Gulbis, Rita Cool, Vi Doan, Terri Lynn Shigle, Whitney Wallis, Ruby Delgado, Sofia Qureshi, Hans C. Lee, Elisabet E. Manasanch, Robert Z. Orlowski, Krina K. Patel, Elizabeth J. Shpall, Borje S. Andersson and Muzaffar Qazilbash
University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center and University of Texas at Houston - MD Anderson Cancer Center
Downloads 72 (860,052)

Abstract:

Loading...

Myeloma, autologous stem-cell transplant, high-dose chemotherapy, phase 2 trial, matched pair comparison